48 related articles for article (PubMed ID: 9517922)
1. Non-responder phenotype reveals apparent microbiome-wide antibiotic tolerance in the murine gut.
Diener C; Hoge ACH; Kearney SM; Kusebauch U; Patwardhan S; Moritz RL; Erdman SE; Gibbons SM
Commun Biol; 2021 Mar; 4(1):316. PubMed ID: 33750910
[TBL] [Abstract][Full Text] [Related]
2. Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.
Rajenderan S; Balaji V; Anandan S; Sahni RD; Tansarli GS; Falagas ME
PLoS One; 2014; 9(7):e103253. PubMed ID: 25068396
[TBL] [Abstract][Full Text] [Related]
3. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents.
Betriu C; Gómez M; Palau ML; Sánchez A; Picazo JJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2320-2. PubMed ID: 10471590
[TBL] [Abstract][Full Text] [Related]
4. An update on the in vitro activity of ceftizoxime and other cephalosporin/cephamycin antimicrobial agents against clinically significant anaerobic bacteria.
Aldridge KE
Clin Ther; 1990; 12 Suppl C():3-12. PubMed ID: 2202509
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility vs. in vivo efficacy of various antimicrobial agents against the Bacteroides fragilis group.
Brook I
Rev Infect Dis; 1991; 13(6):1170-80. PubMed ID: 1775850
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.
Hoellman DB; Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Mar; 42(3):495-501. PubMed ID: 9517922
[TBL] [Abstract][Full Text] [Related]
7. Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Nov; 38(11):2599-604. PubMed ID: 7872754
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
Brown JE; Del Bene VE; Collins CD
Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of 36 antimicrobial agents against clinically isolated Bacteroides fragilis.
Teng LJ; Ho SW; Chang SC; Luh KT; Hsieh WC
J Formos Med Assoc; 1991 Aug; 90(8):796-9. PubMed ID: 1683376
[TBL] [Abstract][Full Text] [Related]
10. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
[TBL] [Abstract][Full Text] [Related]
11. The comparative in-vitro activity of cefotetan against anaerobic bacteria.
Watt B; Brown FV
J Antimicrob Chemother; 1985 Jun; 15(6):671-7. PubMed ID: 3861604
[TBL] [Abstract][Full Text] [Related]
12. Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
Spangler SK; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():23-7. PubMed ID: 9222066
[TBL] [Abstract][Full Text] [Related]
13. Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1997 Apr; 41(4):847-9. PubMed ID: 9087503
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
Appelbaum PC; Spangler SK; Jacobs MR
J Antimicrob Chemother; 1993 Aug; 32(2):223-31. PubMed ID: 8226424
[TBL] [Abstract][Full Text] [Related]
15. Cefminox: correlation between in-vitro susceptibility and pharmacokinetics and serum bactericidal activity in healthy volunteers.
Aguilar L; Esteban C; Frias J; Pérez-Balcabao I; Carcas AJ; Dal-Ré R
J Antimicrob Chemother; 1994 Jan; 33(1):91-101. PubMed ID: 8157579
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
